Novo Nordisk R&D Investor Event ADA 2022

Novo Nordisk presented its innovation and therapeutic focus at an R&D investor event during the American Diabetes Association (ADA) conference in New Orleans on June 5, 2022. The presentation covered the company's research, development, and product strategy across its healthcare portfolio including diabetes and obesity treatments.